A mechanism of rifamycin inhibition and resistance in Pseudomonas aeruginosa

Journal of Antimicrobial Chemotherapy

Volumn 38, Issue 1, 1996, Pages 133-137

  Yee, Ying Cheung ^a   Kisslinger, Benjamin ^b   Yu, Victor L ^a,c   Jin, Ding Jun ^d  

^a UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

^b CARNEGIE MELLON UNIVERSITY   (United States)

^c UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^d NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; DRUG DERIVATIVE; PHOSPHATE; RIFAMPICIN; RIFAMYCIN; RIFAPENTINE; SODIUM POLYMETAPHOSPHATE;

AMINO ACID SEQUENCE; ANTIBIOTIC RESISTANCE; ARTICLE; DRUG EFFECT; GENETIC TRANSCRIPTION; GENETICS; MICROBIOLOGICAL EXAMINATION; MOLECULAR GENETICS; MUTATION; PSEUDOMONAS AERUGINOSA; SEQUENCE HOMOLOGY;

AMINO ACID SEQUENCE; ANTI-BACTERIAL AGENTS; DRUG RESISTANCE, MICROBIAL; MICROBIAL SENSITIVITY TESTS; MOLECULAR SEQUENCE DATA; MUTATION; PHOSPHATES; PSEUDOMONAS AERUGINOSA; RIFAMPIN; RIFAMYCINS; SEQUENCE HOMOLOGY, AMINO ACID; TRANSCRIPTION, GENETIC;

EID: 0030179429     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: 10.1093/jac/38.1.133     Document Type: Article

References (11)

1. Chamberlain, M. J., Nierman, W. C., Wiggs, J. & Neff, N. (1979). A quantitative assay for bacterial RNA polymerase. Journal of Biological Chemistry 254, 100061-9.
2. Guerrero, C., Stockman, L., Marchesi, F., Bodmer, T., Robert, G. D. & Telenti, A. (1993). Evaluation of the rpoB gene in rifampin-susceptible and -resistant Mycobacterium avium and Mycobacterium intracellulare. Journal of Antimicrobial Chemotherapy 33, 661-74.
3. Jin, D. J., & Gross, C. A. (1988). Mapping and sequencing of mutations in the E. coli rpoB gene that leads to rifampin resistance. Journal of Molecular Biology 202, 45-58.
4. National Committee of Clinical Laboratory Standards. (1993). Method for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically, 3rd edn. Approved Standard - Document M7-A3. NCCLS, Villanova, PA.
5. Nicas, T. I. & Hancock, R. E. W. (1983). Pseudomonas aeruginosa outer membrane permeability: isolation of a porin protein F-deficient mutant. Journal of Bacteriology 153, 281-5.
6. Telenti, A., Imboden, P., Marchesi, F., Lowrie, D., Cole, S., Colston, M. J. et al. (1993). Detection of rifampin-resistance mutations in Mycobacterium tuberculosis. Lancet 341, 647-50.
7. Traub, W. H., Spohr, M. & Bauer, D. (1988). Pseudomonas aeruginosa in vitro susceptibility to antimicrobial drugs, single and combined, with and without defibrinated blood. Chemotherapy 34, 284-97.
8. Valdes, J. M., Baltch, A., Smith, R., Hammer, M. C. & Ritz, W. J. (1990). The effect of rifampin on the in vitro activity of cefpirome or ceftazidime in combination with aminoglycosides against Pseudomonas aeruginosa. Journal of Antimicrobial Chemotherapy 25, 565-84.
9. Valdes, J. M., Baltch, A., Smith, R., Franke, M., Ritz, W. J., Williams, S. et al. (1990). Comparative therapy with cefpirome alone and in combination with rifampin and/or gentamicin against disseminated Pseudomonas aeruginosa infection in neutropenic mice. Journal of Infectious Diseases 162, 1112-7.
10. Zuravleff, J. J., Yu, V. L. & Yee, R. B. (1983). Ticarcillin-tobramycin-rifampin: in vitro synergy of the triplet combination against Pseudomonas aeruginosa. Journal of Laboratory Clinical Medicine 101, 906-2.
11. Zuravleff, J. J., Chervenick, P., Yu, V. L. & Muder R. R. (1984). Addition of rifampin to ticarcillin-tobramycin combination for the treatment of Pseudomonas aeruginosa infections: assessment in a neutropenic mouse model. Journal of Laboratory Clinical Medicine 103, 878-85.